Opus Genetics Financials
Opus Genetics (IRD) reported $14.2M in revenue for fiscal year 2025, up 29.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash preservation depends on fundraising because development-stage spending still runs several times ahead of revenue.
Across FY2024-FY2025, net losses of$57.5M and$49.6M were much deeper than operating cash burn of$25.6M and$35.3M , so reported losses did not translate one-for-one into cash drain. But cash stayed high at$45.1M in FY2025 only because financing brought in$50.0M , showing the balance sheet is being maintained externally rather than by operating inflows.
FY2025 revenue of
The company still had a liquidity cushion with
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Opus Genetics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Opus Genetics scores -1.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($303.7M) relative to total liabilities ($34.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Opus Genetics passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Opus Genetics reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Opus Genetics reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Opus Genetics generated $14.2M in revenue in fiscal year 2025. This represents an increase of 29.1% from the prior year.
Opus Genetics's EBITDA was -$38.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.9% from the prior year.
Opus Genetics reported -$49.6M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Cash & Balance Sheet
Opus Genetics held $45.1M in cash against $1.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Opus Genetics's ROE was -323.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 532.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Opus Genetics invested $30.8M in research and development in fiscal year 2025. This represents an increase of 14.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
IRD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.9M | $14.2M+29.1% | $11.0M-42.3% | $19.0M-52.2% | $39.9M+6665.7% | $589K | $0-100.0% | $3.0M | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| R&D Expenses | $38.6M | $30.8M+14.8% | $26.9M+52.1% | $17.7M+23.0% | $14.4M-5.4% | $15.2M+128.2% | $6.6M+21.4% | $5.5M-58.2% | $13.1M+22.3% | $10.7M+6.2% | $10.1M-16.9% | $12.1M+73.2% | $7.0M+115.7% | $3.3M-4.1% | $3.4M-71.7% | $12.0M |
| SG&A Expenses | $21.8M | $22.0M+20.7% | $18.2M+52.3% | $12.0M+64.5% | $7.3M-10.5% | $8.1M+188.2% | $2.8M+54.8% | $1.8M-75.5% | $7.4M+11.9% | $6.6M+5.0% | $6.3M+3.4% | $6.1M-2.2% | $6.3M+32.3% | $4.7M+74.2% | $2.7M-23.5% | $3.5M |
| Operating Income | -$50.6M | -$38.6M+37.8% | -$62.1M-487.7% | -$10.6M-158.0% | $18.2M+180.3% | -$22.7M-13.7% | -$20.0M-376.2% | -$4.2M+79.6% | -$20.5M-18.3% | -$17.4M-5.7% | -$16.4M+10.1% | -$18.3M-37.6% | -$13.3M-66.3% | -$8.0M-21.3% | -$6.6M+59.2% | -$16.1M |
| Interest Expense | N/A | $129K | $0 | $0-100.0% | $9K+350.0% | $2K-100.0% | $6.8M+385.9% | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0-100.0% | $12K-96.2% | $315K | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Net Income | -$107.6M | -$49.6M+13.8% | -$57.5M-476.1% | -$10.0M-155.8% | $17.9M+131.6% | -$56.7M-130.3% | -$24.6M-299.1% | -$6.2M+57.1% | -$14.4M+43.2% | -$25.3M-171.8% | -$9.3M+35.3% | -$14.4M+22.3% | -$18.5M-95.0% | -$9.5M-52.6% | -$6.2M+45.1% | -$11.3M |
| EPS (Diluted) | — | -$0.80 | -$2.15-367.4% | -$0.46-152.9% | $0.87+122.8% | -$3.82 | -$5.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IRD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $50.2M+36.3% | $36.9M-31.7% | $53.9M+10.1% | $49.0M+87.9% | $26.1M+47.5% | $17.7M+891.1% | $1.8M-88.9% | $16.0M-43.3% | $28.3M+34.4% | $21.0M-15.2% | $24.8M-26.0% | $33.5M+71.5% | $19.6M+31.1% | $14.9M+9.0% | $13.7M |
| Current Assets | $50.0M+36.7% | $36.6M-32.1% | $53.9M+10.1% | $49.0M+87.9% | $26.1M+47.5% | $17.7M+902.7% | $1.8M-88.9% | $15.9M-43.5% | $28.1M+34.5% | $20.9M-15.2% | $24.7M-26.2% | $33.4M+73.3% | $19.3M+40.1% | $13.8M+13.3% | $12.2M |
| Cash & Equivalents | $45.1M+48.7% | $30.3M-40.0% | $50.5M+18.5% | $42.6M+73.8% | $24.5M+49.6% | $16.4M+966.9% | $1.5M-82.4% | $8.7M-1.7% | $8.9M-23.1% | $11.6M+13.5% | $10.2M+3.8% | $9.8M-47.4% | $18.7M+38.6% | $13.5M+36.8% | $9.9M |
| Accounts Receivable | $2.0M-44.0% | $3.6M+284.8% | $926K-28.7% | $1.3M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $34.9M+15.8% | $30.1M+645.6% | $4.0M+46.8% | $2.8M-28.6% | $3.9M-87.6% | $31.1M+233.4% | $9.3M-47.3% | $17.7M+54.0% | $11.5M+189.1% | $4.0M-33.9% | $6.0M-13.3% | $7.0M+0.3% | $6.9M+28.7% | $5.4M+80.5% | $3.0M |
| Current Liabilities | $7.8M-31.1% | $11.3M+179.4% | $4.0M+46.8% | $2.8M-28.6% | $3.9M+21.0% | $3.2M-65.9% | $9.3M+196.4% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | $1.1M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $15.3M+128.3% | $6.7M-86.5% | $49.9M+7.9% | $46.2M+108.1% | $22.2M+265.0% | -$13.5M-78.1% | -$7.6M-345.0% | -$1.7M-110.1% | $16.8M-1.7% | $17.1M-9.1% | $18.8M-29.4% | $26.6M+110.5% | $12.6M+32.4% | $9.5M-10.9% | $10.7M |
| Retained Earnings | -$188.6M-35.7% | -$139.0M-70.6% | -$81.5M-14.0% | -$71.5M+20.0% | -$89.4M-173.5% | -$32.7M-305.6% | -$8.1M+94.8% | -$154.7M-10.2% | -$140.3M-22.0% | -$115.0M-8.8% | -$105.7M-15.7% | -$91.3M-25.4% | -$72.8M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill.
IRD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.7M | -$35.3M-37.8% | -$25.6M-2200.0% | -$1.1M-107.8% | $14.3M+173.9% | -$19.4M-185.0% | -$6.8M-89.2% | -$3.6M+80.9% | -$18.8M-22.2% | -$15.4M-16.6% | -$13.2M+23.8% | -$17.4M-57.2% | -$11.0M-38.3% | -$8.0M-20.6% | -$6.6M+57.4% | -$15.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $25K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$6.8M-87.9% | -$3.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0-100.0% | $1.2M | $0 | $0+100.0% | -$100K-118.6% | $539K+2256.0% | -$25K-100.2% | $11.9M+227.1% | -$9.4M | N/A | N/A | N/A | $846K-61.4% | $2.2M+501.2% | -$546K |
| Financing Cash Flow | $97.2M | $50.0M+1095.0% | $4.2M-53.4% | $9.0M+137.2% | $3.8M-86.3% | $27.6M+30.7% | $21.1M+349.0% | $4.7M-30.5% | $6.8M-69.4% | $22.1M | N/A | N/A | N/A | $12.3M+53.2% | $8.1M-40.8% | $13.6M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IRD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.9% | -564.7% | -55.5%-101.2pp | 45.7% | -3854.8% | N/A | -139.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -349.3% | -523.4% | -52.4%-97.3pp | 44.9% | -9625.3% | N/A | -205.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -323.1%+532.5pp | -855.6%-835.6pp | -20.0%-58.7pp | 38.7%+293.8pp | -255.1% | N/A | N/A | N/A | -150.8%-96.3pp | -54.6%+22.1pp | -76.6%-6.9pp | -69.7%+5.6pp | -75.2%-9.9pp | -65.3%+40.7pp | -106.0% |
| Return on Assets | -98.7%+57.4pp | -156.1%-137.6pp | -18.5%-55.0pp | 36.5%+253.9pp | -217.4%-78.2pp | -139.2%+206.6pp | -345.8%-256.2pp | -89.6%-0.1pp | -89.4%-45.2pp | -44.2%+13.8pp | -58.0%-2.8pp | -55.2%-6.7pp | -48.6%-6.8pp | -41.7%+41.1pp | -82.9% |
| Current Ratio | 6.43+3.2x | 3.24-10.1x | 13.35-4.4x | 17.79+11.0x | 6.76+1.2x | 5.55+5.4x | 0.19-4.9x | 5.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.07+0.1x | 0.00-0.1x | 0.080.0x | 0.06-0.1x | 0.17 | N/A | N/A | N/A | 0.69+0.5x | 0.23-0.1x | 0.32+0.1x | 0.26-0.3x | 0.550.0x | 0.56+0.3x | 0.28 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -120.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Opus Genetics Ranks
Frequently Asked Questions
What is Opus Genetics's annual revenue?
Opus Genetics (IRD) reported $14.2M in total revenue for fiscal year 2025. This represents a 29.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Opus Genetics's revenue growing?
Opus Genetics (IRD) revenue grew by 29.1% year-over-year, from $11.0M to $14.2M in fiscal year 2025.
Is Opus Genetics profitable?
No, Opus Genetics (IRD) reported a net income of -$49.6M in fiscal year 2025.
What is Opus Genetics's EBITDA?
Opus Genetics (IRD) had EBITDA of -$38.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Opus Genetics have?
As of fiscal year 2025, Opus Genetics (IRD) had $45.1M in cash and equivalents against $1.1M in long-term debt.
What is Opus Genetics's return on equity (ROE)?
Opus Genetics (IRD) has a return on equity of -323.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Opus Genetics's operating cash flow?
Opus Genetics (IRD) recorded an outflow of $35.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Opus Genetics's total assets?
Opus Genetics (IRD) had $50.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Opus Genetics spend on research and development?
Opus Genetics (IRD) invested $30.8M in research and development during fiscal year 2025.
What is Opus Genetics's current ratio?
Opus Genetics (IRD) had a current ratio of 6.43 as of fiscal year 2025, which is generally considered healthy.
What is Opus Genetics's debt-to-equity ratio?
Opus Genetics (IRD) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Opus Genetics's return on assets (ROA)?
Opus Genetics (IRD) had a return on assets of -98.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Opus Genetics's cash runway?
Based on fiscal year 2025 data, Opus Genetics (IRD) had $45.1M in cash against an annual operating cash burn of $35.3M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Opus Genetics's Altman Z-Score?
Opus Genetics (IRD) has an Altman Z-Score of -1.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Opus Genetics's Piotroski F-Score?
Opus Genetics (IRD) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Opus Genetics's earnings high quality?
Opus Genetics (IRD) reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Opus Genetics cover its interest payments?
Opus Genetics (IRD) reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Opus Genetics?
Opus Genetics (IRD) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.